ABCELLERA BIOLOGICS INC
ABCLNASDAQ🏆 #1337 by market capEarnings Nov 9US Equity
$13.64▲ $0.79 (+6.15%)
Pre-market · at closeTrack ABCL
Get earnings, price moves & breaking news on Telegram
24h▲ 6.2%
7d▲ 19.7%
14d▲ 7.6%
30d▼ 8.0%
ytd▲ 299.9%
1y▲ 142.6%
🏦Market Cap
$4.42B
Small Cap
📈Revenue Growth (YoY)
101.3%
High Growth
📊Gross Margin
—
💵FCF Margin
36.0%
Strong
⚖️P/S Ratio
66.8x
Expensive
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $12.66 – $13.64
- 52-Week Range
- $2.75 – $15.02
- Volume (shares)
- 189,528
- Avg Volume (shares)
- —
- Shares Outstanding
- 323.9M
- Next Earnings
- 2026-11-09
Fundamentals Snapshot
- Annual Revenue
- $75M
- Last Q Revenue
- $4M
- P/E Ratio
- —
- P/S Ratio
- 66.8x
- EPS (TTM)
- $-0.54
- Dividend Yield
- —
- Dilution (1yr)
- +1.4%
ABCELLERA BIOLOGICS INC
ABCLFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$75M▲ +160.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
61.6%▼ −38.4% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$217M▼ −31.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$174M▼ −6.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
298.7M▲ +1.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$15M▼ −$106M YoY
StockOtter · stockotter.spaceAbout ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Buy
17 analysts
Strong Buy3
Buy12
Hold2
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.